We are trying to identify novel or known viruses as causes of diseases of uncertain etiology. Blood and tissues from patients are being examined by sensitive PCR tests in an attempt to find new or known viruses that are responsible for the diseases. Previously, we used these procedures to identify human herpesvirus 6 in lymph node biopsies from three patients who presented with fever and enlarged lymph nodes. Cytomegalovirus causes congenital disease which can result in deafness and mental retardation in neonates, and can cause severe viral pneumonia and colitis in transplant recipients and sight-threatening retinitis in patients with AIDS. Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with a number of cancers including Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkins disease, and post-transplant lymphoproliferative disease. Human CMV and EBV infect humans, but not small animals or nonhuman primates. The best models currently available for CMV and EBV are rhesus monkey CMV and EBV. The goal of this study is to develop an effective vaccine for these rhesus viruses and to use these as a model for vaccines for their human counterparts. We are using various approaches including soluble recombinant proteins, recombinant virus vectors expressing viral proteins, and replication defective viruses as vaccines. We have collaborated with a laboratory at the Food and Drug Adminstration to try to detect viruses in clinical specimens using novel assays that do not depend on known virus sequences or antibodies. In 2009 we isolated DNA and RNA from bronchoalveolar lavage fluid in an immunocompromised patient suffering from pneumonia in whom a causative agent could not be identified by routine methods. cDNA was prepared from the RNA and the polymerase chain reaction was performed using degenerate oligonucleotide primers to amplify the DNA and the cDNA from the broncholalveolar lavage fluid. The PCR products were cloned and sequenced and human metapneumovirus was identified by sequence analysis. Therefore this procedure should be able to identify new viruses in clinical specimens. We are currently using this system to try to identify viruses in other clinical specimens in which an infectious microorganism has not been able to be identified.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2009
Total Cost
$502,485
Indirect Cost
City
State
Country
Zip Code
Cohen, Jeffrey I (2018) Vaccine Development for Epstein-Barr Virus. Adv Exp Med Biol 1045:477-493
Li, Qingxue; Bu, Wei; Gabriel, Erin et al. (2017) HLA-DQ?1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells. JCI Insight 2:e85687
Burbelo, Peter D; Gunti, Sreenivasulu; Keller, Jason M et al. (2017) Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. Sci Rep 7:3818
Cohen, Jeffrey I (2017) GATA2 Deficiency and Epstein-Barr Virus Disease. Front Immunol 8:1869
Coghill, Anna E; Bu, Wei; Nguyen, Hanh et al. (2016) High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. Clin Cancer Res 22:3451-7
Bu, Wei; Hayes, Gregory M; Liu, Hui et al. (2016) Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV. Clin Vaccine Immunol 23:363-9
Li, Qingxue; Fischer, Elizabeth; Cohen, Jeffrey I (2016) Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-Like Process. J Virol 90:9766-9781
Li, Qingxue; Wilkie, Adrian R; Weller, Melodie et al. (2015) THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection. PLoS Pathog 11:e1004999
Kanekiyo, Masaru; Bu, Wei; Joyce, M Gordon et al. (2015) Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 162:1090-100
Cohen, Jeffrey I (2015) Epstein-barr virus vaccines. Clin Transl Immunology 4:e32

Showing the most recent 10 out of 23 publications